Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NCAM agonists - ENKAM Pharmaceuticals

Next Previous
Search
Drug Profile

Research programme: NCAM agonists - ENKAM Pharmaceuticals

Alternative Names: Dennexin; Fibroblast growth factor (FGF) receptor agonists - ENKAM; NCAM mimetic peptides; NCAM mimetics; P2; P2-peptide; Plannexin; TBI therapeutics - ENKAM; Traumatic brain injury therapeutics - ENKAM

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Fibroblast growth factor receptor agonists; Neural cell adhesion molecule agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in Denmark (SC, Injection)
  • 27 May 2011 Preclinical development is ongoing in Denmark
  • 07 Nov 2007 Pharmacodynamics data from a preclinical trial presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top